Overview

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

Status:
Completed
Trial end date:
2020-02-19
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with Parkinson's Disease (PD).
Phase:
Phase 1
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.